Upregulation of CD40--CD40 ligand system in patients with diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CCCN.2003.09.007PMID 14687897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c.

  2009cited by this paper
• Soluble CD40 ligand in acute coronary syndromes.

  2003cited by this paper
• Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

  2003cited by this paper
• Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones

  2003cited by this paper
• Impaired vascular reactivity is present despite normal levels of von Willebrand factor in patients with uncomplicated Type 2 diabetes

  2002cited by this paper
• CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells.

  2002cited by this paper
• Inflammation and Atherosclerosis

  2002cited by this paper
• , Hypercholesterolemia : Effects of Statin Therapy Association Between Enhanced Soluble CD 40 L and Prothrombotic State in

  2002cited by this paper
• Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes

  2002cited by this paper
• Clinical implications of increased expression of CD40L in patients with acute coronary syndromes.

  2002cited by this paper
• CD154-dependent priming of diabetogenic CD4(+) T cells dissociated from activation of antigen-presenting cells.

  2002cited by this paper
• Soluble CD40L and Cardiovascular Risk in Women

  2001cited by this paper
• The CD40/CD154 receptor/ligand dyadRID="†"ID="†" Review

  2001cited by this paper
• Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

  2000cited by this paper
• Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes

  2000cited by this paper
• Evaluation of platelet function by flow cytometry.

  2000cited by this paper
• Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.

  1999cited by this paper
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus.

  1997cited by this paper
• Advanced glycation end products, oxidant stress and vascular lesions

  1997cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper
• Immunochemical detection of advanced glycosylation end products in vivo.

  1992cited by this paper

• Hyperactivity and Pro-inflammatory Functions of Platelets in Diabetes.

  2025cites this paper
• Inhibition of platelet activation alleviates diabetes-associated cognitive dysfunction via attenuating blood-brain barrier injury.

  2025cites this paper
• Impact of the -1T>C single-nucleotide polymorphism of the CD40 gene on the development of endothelial dysfunction in a pro-diabetic microenvironment.

  2023cites this paper
• Diabetes, Diabetic Retinopathy, and Inflammatory Disorders

  2023cites this paper
• CD40 Ligand–CD40 Interaction Is an Intermediary between Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy

  2023cites this paper
• Non-hemostatic functions of human blood platelets : Effects of bioactive compounds 1 2

  2022influential citation
• Bioactive food components and their inhibitory actions in multiple platelet pathways.

  2022cites this paper
• Platelet Dependent Thrombogenicity, Inflammation and Five Year Mortality in Patients with Non-ST Elevation Acute Coronary Syndrome and Type 2 Diabetes Mellitus: An Observational Study

  2022cites this paper
• Evaluation of soluble CD40L in children with type 1 diabetes mellitus and its relation to diabetes associated vasculopathy

  2021cites this paper
• The Proinflammatory Soluble CD40 Ligand Is Associated with the Systemic Extent of Stable Atherosclerosis

  2021cites this paper
• Association of CD40 rs1883832 Polymorphism with Susceptibility of Diabetic Nephropathy and Neuropathy in Egyptian Population.

  2020cites this paper
• The Role of Platelets in Diabetes Mellitus

  2019cites this paper
• 4 The Role of T Cells in Type 1 Diabetes

  2018cites this paper
• Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to Diabetogenesis

  2017cites this paper
• Technology Medicine Open Access book

  2017cites this paper
• The association between impaired glucose tolerance and soluble CD40 ligand: a 15-year prospective cohort study

  2016cites this paper
• P hromboxane-Dependent CD 40 igand Release in Type 2 Diabetes Mellitus

  2016cites this paper
• Blood cell changes in complement activation-related pseudoallergy

  2015cites this paper
• Platelets and diabetes mellitus.

  2015cites this paper
• Identification of novel mechanisms of glucolipotoxicity in type 2 diabetes

  2015influential citation
• Overview of Platelet Physiology: Its Hemostatic and Nonhemostatic Role in Disease Pathogenesis

  2014cites this paper
• Multifunctional CD40L: pro- and anti-neoplastic activity

  2014cites this paper
• Dysregulation of monocyte biology in metabolic syndrome

  2014cites this paper
• Circulating high-sensitivity C-reactive protein and soluble CD40 ligand are inter-related in a cohort of women with polycystic ovary syndrome.

  2013cites this paper
• Platelet Cd Markers By Flow Cytometry In Normal Individuals And In Patients With Untreated Type 2 Diabetes Mellitus

  2013cites this paper
• Chapter 35 – Diabetes Mellitus

  2013cites this paper
• Regression of atherosclerosis plaques in apolipoprotein E-/- mice after lentivirus-mediated RNA interference of CD40.

  2013cites this paper
• Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology

  2013cites this paper
• Platelets as a Novel Target for PPARγ Ligands

  2012cites this paper
• Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities

  2012cites this paper
• PLATELETS STRUCTURAL, FUNCTIONAL AND METABOLIC ALTERATIONS IN DIABETES MELLITUS

  2012cites this paper
• Diabetes mellitus ist assoziiert mit einer erhöhten Plättchenaggregation: Pathophysiologische Aspekte und Rolle der antithrombotischen Therapie

  2012cites this paper
• Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control

  2012cites this paper
• The Role of T Cells in Type 1 Diabetes

  2012cites this paper
• Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.

  2011cites this paper
• Система CD40 - лиганд CD40 в развитии сахарного диабета и его осложнений

  2011cites this paper
• The Role of T Cells in Type 1 Diabetes

  2011cites this paper
• The role of CD40 receptor-ligand system in the development of diabetes mellitus and its complications

  2011cites this paper
• Inflammatory biomarkers and coronary restenosis in patients with type-2 diabetes

  2010cites this paper
• Novel systemic cardiovascular disease biomarkers.

  2010cites this paper
• The Levels of Soluble CD40 Ligand and C-Reactive Protein in Normal Weight, Overweight and Obese People

  2010cites this paper
• CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity.

  2010cites this paper
• Diabetes is a proinflammatory state: a translational perspective

  2010cites this paper
• Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome.

  2010cites this paper
• Platelets : with special reference to platelet density subpopulations, stable coronary heart disease and atrial fibrillation

  2010cites this paper
• The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time

  2010cites this paper
• STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects

  2010cites this paper
• Association between serum levels of soluble CD40/CD40 ligand and organ damage in hypertensive patients

  2010cites this paper
• Differential regulation of TLR4 expression in human B cells and monocytes.

  2010cites this paper
• Soluble CD40 Ligand, Plasminogen Activator Inhibitor-1 and Thrombin-Activatable Fibrinolysis Inhibitor-1-Antigen in Normotensive Type 2 Diabetic Subjects without Diabetic Complications

  2009cites this paper
• C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients.

  2009cites this paper
• CD40/CD40L signaling and its implication in health and disease

  2009cites this paper
• CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mononuclear cells.

  2009cites this paper
• Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome.

  2008cites this paper
• High Distribution of CD40 and TRAF2 in Th40 T Cell Rafts Leads to Preferential Survival of this Auto-Aggressive Population in Autoimmunity

  2008cites this paper
• Acute Suppression of Circulating sCD40L During Hyperglycemia and Euglycemic-Hyperinsulinemia in Healthy Young Males

  2008cites this paper
• Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.

  2008cites this paper
• CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease.

  2008cites this paper
• The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands.

  2007cites this paper
• Endothelin-1 induces functionally active CD40 protein via nuclear factor-kappaB in human vascular smooth muscle cells.

  2007cites this paper
• Relationship between upregulation of CD40 system and restenosis in patients after percutaneous coronary intervention

  2007cites this paper
• Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.

  2007cites this paper
• 166 Trombocyty a CD 40 / CD 40-ligand-závislá signalizácia v procese aterotrombózy

  2007cites this paper
• Increased expression of CD40 ligand and C-reactive protein in patients with restenosis after percutaneous coronary intervention

  2007cites this paper
• Trombocyty a CD40/CD40-ligand-závislá signalizácia v procese aterotrombózy

  2007cites this paper
• CD40/CD40L system and vascular disease

  2007cites this paper
• Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.

  2006cites this paper
• Platelet resistance to the anti-aggregating agents in the insulin resistant states.

  2006cites this paper
• Chapter 8 – Diabetes and Inflammation

  2006cites this paper
• Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand.

  2006cites this paper
• The clinical implications of increased coexpression of CD40-CD40 ligand system and C-reactive protein in patients after percutaneous coronary intervention.

  2006cites this paper
• Signatures of human regulatory T cells: an encounter with old friends and new players

  2006influential citation
• Soluble CD 40 L Levels Are Regulated by the 3459 A > G Polymorphism and Predict Myocardial Infarction and the Efficacy of Antithrombotic Treatment in Non-ST Elevation Acute Coronary Syndrome

  2006cites this paper
• Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes.

  2006cites this paper
• Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease.

  2006cites this paper
• Soluble CD40L Levels Are Regulated by the −3459 A>G Polymorphism and Predict Myocardial Infarction and the Efficacy of Antithrombotic Treatment in Non-ST Elevation Acute Coronary Syndrome

  2006cites this paper
• Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells.

  2005cites this paper
• PLATELET FUNCTION IN DIABETES MELLITUS

  2005cites this paper
• Use of low concentrations of human IgA anti-tissue transglutaminase to rule out selective IgA deficiency in patients with suspected celiac disease.

  2005cites this paper
• Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study

  2005cites this paper
• Soluble CD 40 Ligand Measurement Inaccuracies Attributable to Specimen Type , Processing Time , and ELISA Method

  2005cites this paper
• Genetics and molecular biology.

  2005cites this paper
• Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method.

  2005cites this paper
• Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease.

  2005cites this paper
• CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates

  2005cites this paper
• Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid.

  2005cites this paper
• Evaluation of a new CA15-3 protein assay method: optical protein-chip system for clinical application.

  2005cites this paper
• Increased levels of CD40-CD40 ligand system in patients with essential hypertension.

  2005cites this paper
• Immunotherapy Targeting the CD40/CD154 Costimulatory Pathway for Treatment of Autoimmune Disease

  2004cites this paper